Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash, FDIC insured amount	$ 250,000
Operating loss carryforwards			$ 910,000
Income tax percentage	21.00%	21.00%		34.00%
Deferred tax assets and liabilities				$ 14,500,000
Income tax benefit	$ 0	$ 0	$ 0	0
Tax benefits of R&D	3,400,000
Advertising expense
Common Stock [Member] | Stock Options and Warrants [Member]
Potentially dilutive securities	14,811,333
Series B Convertible Preferred Stock [Member]
Potentially dilutive securities	1,700,000
Series B Convertible Preferred Stock [Member] | Common Stock [Member]
Number of shares converted during period	150,442,478
Convertible Series A Preferred Stock [Member] | Nostrum Pharmaceuticals, LLC [Member]
Potentially dilutive securities	220
California Franchise Tax Board [Member]
Adjustment of valuation allowance	$ 3,600,000
Federal [Member]
Operating loss carryforwards	$ 92,066,000	91,400,000
Operating loss carryforwards expiration, description	The net operating losses begin to expire in 2023 for federal income purposes
Adjustment of valuation allowance	$ 19,100,000
Federal [Member] | Research and Development Credit [Member]
Income tax credits	$ 1,800,000
Income tax credits, expiration date	Dec. 31, 2035
State [Member]
Operating loss carryforwards	$ 53,160,000	$ 52,500,000
Operating loss carryforwards expiration, description	In 2028 for state income tax purposes.
State [Member] | Research and Development Credit [Member]
Income tax credits	$ 1,900,000
Minimum [Member]
Property and equipment, estimated useful life	3 years
Maximum [Member]
Property and equipment, estimated useful life	5 years